VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao

Stock News

11/03

VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.

The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.

The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.

VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1101244851"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101244851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101244851?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101244851","market":"sg","top_or_hot":-1,"title":"VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao","media":"Stock News","content":"<p>VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.</p>\n<p>The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.</p>\n<p>The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.</p>\n<p>VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-11-03 10:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.</p>\n<p>The drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.</p>\n<p>The company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.</p>\n<p>VISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"維升藥業-B","start_time":0,"source_url":"","article_id":"1101244851","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101244851","pubTimestamp":1762136899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B","BK1161":"生物科技"},"translate_title":"帕洛培特立帕肽在博鳌完成首个处方，维森制药-B(02561)涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at Ruijin Hospital Hainan Hospital (Boao Research Hospital) under Shanghai Jiao Tong University School of Medicine.\nThe drug, already approved in major European and American markets, is the world's first and only hormone replacement therapy for hypoparathyroidism. CEO and Executive Director Lu Anbang emphasized that this milestone underscores VISEN PHARMA's commitment to innovation in endocrinology. The breakthrough therapy aims to alleviate challenges faced by patients under conventional treatments.\nThe company plans to accelerate domestic approval through collaborations while expanding its pipeline. Its most advanced candidate, Lonapegsomatropin (long-acting growth hormone), is expected to launch domestically in H2 2025 as China's third long-acting growth hormone therapy.\nVISEN PHARMA's portfolio includes two unique candidates: Navipeptide and Palopegteriparatide, with the latter targeting a 2025 year-end NDA submission. Earlier partnerships with WuXi Biologics (June 2024) for localized production and Anke Biotechnology (July 2024) for commercialization highlight its strategy to deliver cost-effective therapies to patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}